Platelet-Rich Plasma

Platelet-rich plasma (PRP) is an autologous blood-derived product characterized by a concentration of platelets that is at least two to three times higher than normal levels, along with various growth factors and cytokines. Researchers primarily study PRP for its potential regenerative effects across multiple medical fields, including orthopedics, dermatology, and sports medicine. Key findings from the literature indicate that PRP may play a role in reducing inflammation, promoting tissue repair, and enhancing healing processes in various conditions, such as osteoarthritis and skin rejuvenation. Current research status reveals a growing interest in standardizing treatment protocols and exploring new applications, although the evidence remains mixed regarding its efficacy in certain areas. Clinical evidence indicates that while PRP is widely accepted as a therapeutic option, further large-scale randomized trials are needed to fully elucidate its benefits and limitations.

Platelet-rich plasma (PRP) is an autologous blood-derived product characterized by a high concentration of platelets and associated growth factors. It is produced by centrifuging whole blood to concentrate platelets, which are then activated to release growth factors and cytokines. PRP is categorized under growth factors due to its regenerative properties. Researchers have explored its use since the 1970s, initially in hematology, and later expanding to various medical fields including orthopedics, dermatology, and aesthetic medicine. PRP plays a significant role in tissue regeneration and healing. It has been extensively researched for its application in orthopedic injuries, dermatological conditions like hair restoration and skin rejuvenation, and other areas such as sports medicine and surgery. PRP's mechanism of action involves the release of growth factors that modulate inflammation, promote angiogenesis, and stimulate cellular proliferation and matrix formation. These processes contribute to tissue repair and regeneration. Researchers have observed that PRP acts through pathways involving cellular proliferation, collagen synthesis, and angiogenesis, among others. Pharmacokinetic properties of PRP are not well-defined due to its autologous nature and localized application. Typically, PRP is prepared and administered at the point of care, with its effects dependent on the concentration of platelets and growth factors. Clinically, PRP is used in various therapeutic settings, although large-scale randomized clinical trials are limited. Regulatory standing varies by region, with PRP often considered a medical procedure rather than a drug, thus not requiring specific drug approval but adhering to medical device regulations.

PRP acts primarily through the release of growth factors such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors activate cellular pathways that promote angiogenesis, cell proliferation, and matrix remodeling, essential for tissue regeneration and healing.

Platelet-rich plasma (PRP) exerts its effects primarily through the binding of growth factors, such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β), to their respective receptors, activating signaling pathways including the MAPK/ERK pathway and the PI3K/Akt pathway, which promote cellular proliferation, angiogenesis, and collagen synthesis. Additionally, PRP modulates inflammation through cytokine release and may enhance tissue regeneration via mechanisms involving the Wnt/β-catenin signaling pathway. While the precise molecular interactions and all signaling pathways involved remain incompletely understood, the regenerative potential of PRP is attributed to its ability to create a favorable microenvironment for tissue healing and repair.

Current evidence is limited regarding the optimal treatment protocols for platelet-rich plasma (PRP) therapy across various medical fields, particularly in dermatology and orthopedics, where standardization is crucial for efficacy. Further research is needed to conduct larger randomized controlled trials (RCTs) that address the conflicting findings related to PRP's effectiveness in specific conditions, such as tendinopathies and osteoarthritis in various joints beyond the knee. Additionally, long-term data is required to assess the durability of PRP's therapeutic effects and its safety profile in diverse patient populations, including those with comorbidities or varying age groups.